Skip to main content
Premium Trial:

Request an Annual Quote

Hepregen, Hamner Institutes Collaborate on Microliver R&D

NEW YORK (GenomeWeb News) – Hepregen and The Hamner Institutes for Health Sciences today announced a deal aimed at research to be conducted by the two partners.

Under the terms of the agreement, the two entities will carry out R&D work directed at defining the basic concepts "regarding the potential for new microliver products," and new applications and assay methods for Hepregen's existing microliver products.

The research will be led by Edward LeCluyse, associate investigator at Hamner, and Jack McGeehan, Hepregen's VP of Operations.

Financial and other terms of the deal were not disclosed.

Medford, Mass.-based Hepregen develops bioengineered microliver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic, and diagnostic product development. The company was spun out by Battelle Ventures in 2009.

Hamner, headquartered in Research Triangle Park, N.C., is a non-profit translational biomedical research institute.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.